Tech Company Financing Transactions
EyeGate Pharmaceuticals Funding Round
Medicis Capital, private investors and Ventech participated in a $15 million Series C capital raise for EyeGate Pharmaceuticals. The round was announced on 3/12/2008.
Transaction Overview
Company Name
Announced On
3/12/2008
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series C
Investors
Medicis Capital (Kai Deusch)
Ventech (Alain Maiore)
Proceeds Purpose
Stephen From, President and Chief Executive Officer of EyeGate Pharma, commented, "Withthis venture financing, EyeGate will enter into two Phase II clinical studies utilizing theEyeGate II Delivery System and a proprietary formulation of a corticosteroid. In the first half of2008 we will initiate a Phase II trial in severe uveitis, and in the second half of the year we willinitiate a Phase II trial in dry eye. EyeGate is well on its way to becoming a leader inophthalmic drug development and the delivery partner of choice for ophthalmic drugdevelopers."
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
271 Waverley Oaks Rd. 108
Waltham, MA 02452
USA
Waltham, MA 02452
USA
Phone
Website
Email Address
Not Recorded
Overview
EyeGate Pharma (NASDAQ: EYEG) is a late-stage specialty pharmaceutical and drug delivery company focused on developing and commercializing therapeutics and drug delivery mechanisms for treating diseases of the eye.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen From
Chief Financial Officer
Sarah Romano
VP - Engineering
Michael Manzo
VP - Operations
Lisa Brandano
VP - R & D
Brenda Mann
Browse more venture capital transactions:
Prev: 3/11/2008: Fluid Entertainment venture capital transaction
Next: 3/12/2008: Pancetera venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs